Publications
Page 2 of 3
April 12, 2021
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here we report the findings of…
Journal: Nature Biotechnology
September 25, 2020
pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model
Huntington disease (HD), a devastating hereditary neurodegenerative disorder, is caused by an expansion of a CAG trinucleotide repeat that encodes a polyglutamine (polyQ) tract in the huntingtin (HTT) gene.
Journal: Cell Death & Disease
June 25, 2020
Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)
The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease-2019…
Journal: Journal of Translational Medicine
May 26, 2020
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune…
Journal: Leukemia
May 21, 2018
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
Huntington Disease (HD) is an incurable autosomal dominant neurodegenerative disorder driven by an expansion repeat giving rise to the mutant huntingtin protein (mHtt), which is known to disrupt a multitude…
Journal: Molecular Neurodegeneration
March 15, 2018
Integrity, standards, and QC-related issues with big-data in pre-clinical drug discovery
The tremendous expansion of data analytics and public and private big datasets presents an important opportunity for pre-clinical drug discovery and development. In the field of life sciences, the growth…
Journal: Biochemical Pharmacology
December 8, 2017
The international MAQC Society launches to enhance reproducibility of high-throughput technologies
Reproducibility is a fundamental hallmark of good science. The US Food and Drug Administration (FDA)-led Microarray and Sequencing Quality Control (MAQC/SEQC) consortia conducted three projects 1,2,3 to assess the reliability and…
Journal: Nature Biotechnology
December 7, 2017
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the…
Journal: JCI Insight
November 23, 2017
Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.
Copaxone (glatiramer acetate, GA), a structurally and compositionally complex polypeptide nonbiological drug, is an effective treatment for multiple sclerosis, with a well-established favorable safety profile. The short antigenic polypeptide sequences…
Journal: Annals of the New York Academy of Sciences
May 18, 2017
Drug repurposing from the perspective of pharmaceutical companies
Drug repurposing holds the potential to bring medications with known safety profiles to new patient populations. Numerous examples exist for the identification of new indications for existing molecules, most stemming…
Journal: British Journal of Pharmacology
Page 2 of 3
